Clinical Trial Detail

NCT ID NCT01719380
Title Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

Therapies

Cetuximab + Encorafenib

Alpelisib + Cetuximab + Encorafenib

Age Groups: adult

Additional content available in CKB BOOST